Hamilton James C 4
4 · ARROWHEAD PHARMACEUTICALS, INC. · Filed Mar 9, 2026
Research Summary
AI-generated summary of this filing
Arrowhead (ARWR) CMO James C. Hamilton Sells 10,000 Shares
What Happened James C. Hamilton, Chief Medical Officer of Arrowhead Pharmaceuticals (ARWR), sold 10,000 shares on 2026-03-05 in an open-market/private sale. The weighted-average sale price was $64.19 per share, for proceeds of approximately $641,900. This was a sale (not a purchase or exercise).
Key Details
- Transaction date: 2026-03-05; Form 4 filed: 2026-03-09 (filed within the required two business days).
- Price: weighted average $64.19; individual trades ranged from $63.80 to $64.51 (report notes full per-price breakdown available on request).
- Shares disposed: 10,000 (transaction code S = sale).
- Shares owned after transaction: not specified in the provided filing.
- Footnotes: (F1) Shares were sold pursuant to a pre-established Rule 10b5-1 trading plan; (F2) weighted-average price reported and per-share price range disclosed; (F3) ownership reported may include previously disclosed RSU awards, some of which remain subject to vesting.
Context Sales executed under a 10b5-1 plan are pre-planned trades and are often routine; they do not necessarily indicate a change in the insider’s view of the company. For retail investors, open-market purchases typically carry more direct informational weight than routine sales.
Insider Transaction Report
Form 4
Hamilton James C
Chief Medical Officer
Transactions
- Sale
Common Stock
[F1][F2][F3]2026-03-05$64.19/sh−10,000$641,900→ 236,958 total
Footnotes (3)
- [F1]Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
- [F2]The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $63.80 to $64.51, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
- [F3]Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions.
Signature
/s/James Hamilton|2026-03-09